Terkko Navigator / -/ Feeds / " ( ( Neuronaaliset seroidilipofuskinoosit )|( neuronal ceroid lipofuscinos )|( Kufs sjukd"

Batten disease (JNCL) is linked to disturbances in mitochondrial, cytoskeletal, and synaptic compartments.

Batten disease (JNCL) is linked to disturbances in mitochondrial, cytoskeletal, and synaptic compartments

Transmembrane Batten disease proteins interact with a shared network of vesicle sorting proteins to regulate synaptic composition and function.

Experience over 17 years with antioxidant treatment in Spielmeyer-Sjögren disease

Novel interactions of CLN3 protein link Batten disease to dysregulation of fodrin-Na+, K+ ATPase complex

AP-1 and AP-3 facilitate lysosomal targeting of Batten disease protein CLN3 via its dileucine motif

Interconnections of CLN3, Hook1 and Rab proteins link Batten disease to defects in the endocytic pathway

IJERPH, Vol. 19, Pages 5895: Towards Understanding Behaviour and Emotions of Children with CLN3 Disease (Batten Disease): Patterns, Problems and Support for Child and Family

IJERPH, Vol. 19, Pages 5895: Towards Understanding Behaviour and Emotions of Children with CLN3 Disease (Batten Disease): Patterns, Problems and Support for Child and Family

The Batten disease protein CLN3 is important for stress granules dynamics and translational activity.

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease

Modulation of CRMP2 via (<em>S</em>)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease